As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...
DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...
ILMN and Nashville Biosciences, LLC (NashBio) recently announced that 250,000 whole genomes have been sequenced for the Alliance for Genomic Discovery (AGD) initiative. The insights from the AGD ...
We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...
Recent News: On March 20, CVS Health reported its board of directors has approved a quarterly dividend of 66.5 cents per share on the Common Stock of the Corporation. Edge Stock Ratings: 62.89 ...
Research in mice identifies protein responsible for regulating gut movement in response to pressure, exercise, and ...
But what it does have is its critical role—albeit underrated—as a biotech hub. Competing with South San Francisco and Boston, ...
Nothing drives down a drug’s price like competition. According the U.S. Food and Drug Administration (FDA), a drug’s ...
Lexicon Pharmaceuticals and Bristol-Myers Squibb, though both in pharma, are leagues apart in scale, profitability, and risk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback